Carvykti, Infusionsdispersion

7680679560017 CH-67956 Beutel
Carvykti, Infusionsdispersion
Carvykti, Infusionsdispersion
1 / 2
google

Article details

Package size
1x30 oder 70ml
Selling units
30
Measure
Beutel
Galenic form
Beutel
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
09/10/2026
Summary of Product Characteristics
Français
09/10/2026
Summary of Product Characteristics
Italien
09/10/2026
Patient information leaflet
Allemand
28/10/2025
Patient information leaflet
Français
28/10/2025
Patient information leaflet
Italien
28/10/2025

Detailed composition

Substance Quantity Type Category
ciltacabtagenum autoleucelum
- Substance Wirkstoff (Principe actif)
CryoStor CS5
- Substance HIMDK

Authorization holder

Janssen-Cilag AG

6300 Zug

Authorization information

Swissmedic authorization number
67956
Drug name
Carvykti, Infusionsdispersion
Galenic form
INLFS
ATC Code
L01XL05
Authorization status
Z
Dispensing category
A
First authorization
08/08/2022
Authorization expiration date
07/08/2027
IT Number
07.16.4.
Domain
Human medicine
Field of application
Carvykti ist für die Behandlung von erwachsenen Patienten mit rezidiviertem und refraktärem multiplem Myelom indiziert, die zuvor mindestens zwei Therapielinien erhalten haben, inklusive einem immunmodulatorischen Wirkstoff, einem Proteasom-Inhibitor und einem Anti-CD38-Antikörper, und welche refraktär zu Lenalidomid sind.

Package details

Description (FR)
CARVYKTI sol inj 2.1-39 × 10e6 ml 1x30oder70ml pce
Description (DE)
CARVYKTI Inj Lös 2.1-39 × 10e6 ml 1x30oder70ml Stk
Market launch
03/09/2024
Narcotic (BTM)
No

Application methods

IV

Other package sizes (1)

None
None None
GTIN: None
Not in V1
Buy us a coffee Explore the data